Arbutus Biopharma Corporation

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for infectious diseases, specifically chronic Hepatitis B virus (HBV). Its pipeline includes Imdusiran, a subcutaneously-delivered RNAi therapeutic product candidate currently in Phase 2a clinical trials, which aims to suppress all HBV antigens, including HBsAg expression. Additionally, the company is developing AB-101, an oral PD-L1 inhibitor in Phase 1a/1b clinical trials, designed to reawaken patients' HBV-specific immune response by inhibiting PD-L1. Arbutus also has a licensing agreement with Alnylam Pharmaceuticals to develop and commercialize products using LNP delivery technology.

Arbutus Biopharma Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ABUS. Its shares are traded in United States Dollars (USD), as the company is based in the United States. The exchange is a major U.S. stock exchange, providing liquidity and visibility for the company's stock.

Arbutus Biopharma Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on research and development of novel therapeutics for infectious diseases, particularly chronic Hepatitis B virus. Biotechnology companies like Arbutus typically engage in drug discovery, preclinical and clinical development, and may seek regulatory approval for their product candidates.

Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania, United States. The company was originally incorporated in 2005 under the name Tekmira Pharmaceuticals Corporation. It rebranded as Arbutus Biopharma Corporation in July 2015. The company's focus has been on developing therapies for infectious diseases, with a primary emphasis on chronic Hepatitis B virus. Its location in the United States allows it to operate within the U.S. regulatory and healthcare environment.

As a clinical-stage biopharmaceutical company, Arbutus Biopharma Corporation does not yet have approved products on the market, so it does not generate revenue from product sales. Instead, its business model involves advancing its pipeline of therapeutic candidates through clinical trials with the goal of obtaining regulatory approval and eventually commercializing them. The company may also generate revenue through licensing agreements, such as its agreement with Alnylam Pharmaceuticals to develop and commercialize products using LNP delivery technology. Additionally, Arbutus may seek partnerships or collaborations to fund research and development activities.